These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 28055963)

  • 1. Emetine elicits apoptosis of intractable B-cell lymphoma cells with MYC rearrangement through inhibition of glycolytic metabolism.
    Aoki T; Shimada K; Sakamoto A; Sugimoto K; Morishita T; Kojima Y; Shimada S; Kato S; Iriyama C; Kuno S; Harada Y; Tomita A; Hayakawa F; Kiyoi H
    Oncotarget; 2017 Feb; 8(8):13085-13098. PubMed ID: 28055963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
    Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
    Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary Cutaneous Diffuse Large B-Cell Lymphoma With a MYC-IGH Rearrangement and Gain of BCL2: Expanding the Spectrum of MYC/BCL2 Double-Hit Lymphomas.
    Testo N; Olson LC; Subramaniyam S; Hanson T; Magro CM
    Am J Dermatopathol; 2016 Oct; 38(10):769-74. PubMed ID: 27391453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma.
    Green TM; Nielsen O; de Stricker K; Xu-Monette ZY; Young KH; Møller MB
    Am J Surg Pathol; 2012 Apr; 36(4):612-9. PubMed ID: 22314191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma.
    Ravi D; Beheshti A; Abermil N; Passero F; Sharma J; Coyle M; Kritharis A; Kandela I; Hlatky L; Sitkovsky MV; Mazar A; Gartenhaus RB; Evens AM
    Cancer Res; 2016 Jun; 76(11):3319-31. PubMed ID: 26988986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma.
    Shin DY; Kim A; Kang HJ; Park S; Kim DW; Lee SS
    Cancer Lett; 2015 Aug; 364(2):89-97. PubMed ID: 25790907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Significance of myc gene rearrangement and its correlation with prognosis in diffuse large B cell lymphoma].
    Zhang HW; Chen ZW; He JX; Zheng YP; Han WE; Zhao ZQ; Bai W; Wang JF
    Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):119-23. PubMed ID: 23714666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffuse large B-cell lymphoma with MYC gene rearrangements: Current perspective on treatment of diffuse large B-cell lymphoma with MYC gene rearrangements; case series and review of the literature.
    de Jonge AV; Roosma TJ; Houtenbos I; Vasmel WL; van de Hem K; de Boer JP; van Maanen T; Lindauer-van der Werf G; Beeker A; Timmers GJ; Schaar CG; Soesan M; Poddighe PJ; de Jong D; Chamuleau ME
    Eur J Cancer; 2016 Mar; 55():140-6. PubMed ID: 26820684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression.
    Sasaki N; Kuroda J; Nagoshi H; Yamamoto M; Kobayashi S; Tsutsumi Y; Kobayashi T; Shimura Y; Matsumoto Y; Taki T; Nishida K; Horiike S; Akao Y; Taniwaki M
    Exp Hematol; 2011 Aug; 39(8):817-28.e1. PubMed ID: 21640157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline.
    Pulvino M; Chen L; Oleksyn D; Li J; Compitello G; Rossi R; Spence S; Balakrishnan V; Jordan C; Poligone B; Casulo C; Burack R; Shapiro JL; Bernstein S; Friedberg JW; Deshaies RJ; Land H; Zhao J
    Oncotarget; 2015 Jun; 6(17):14796-813. PubMed ID: 26142707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Significance and application of c-myc in diffuse large B-cell lymphoma].
    Huang WT; Lü N; Guo L
    Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):638-40. PubMed ID: 24314257
    [No Abstract]   [Full Text] [Related]  

  • 12. A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.
    Abate F; Todaro M; van der Krogt JA; Boi M; Landra I; Machiorlatti R; Tabbò F; Messana K; Abele C; Barreca A; Novero D; Gaudiano M; Aliberti S; Di Giacomo F; Tousseyn T; Lasorsa E; Crescenzo R; Bessone L; Ficarra E; Acquaviva A; Rinaldi A; Ponzoni M; Longo DL; Aime S; Cheng M; Ruggeri B; Piccaluga PP; Pileri S; Tiacci E; Falini B; Pera-Gresely B; Cerchietti L; Iqbal J; Chan WC; Shultz LD; Kwee I; Piva R; Wlodarska I; Rabadan R; Bertoni F; Inghirami G;
    Leukemia; 2015 Jun; 29(6):1390-401. PubMed ID: 25533804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dracocephalum palmatum Stephan extract induces caspase‑ and mitochondria‑dependent apoptosis via Myc inhibition in diffuse large B cell lymphoma.
    Kim J; Kim JN; Park I; Sivtseva S; Okhlopkova Z; Zulfugarov IS; Kim SW
    Oncol Rep; 2020 Dec; 44(6):2746-2756. PubMed ID: 33125144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of MYC rearrangement in high grade B cell lymphomas: correlation of MYC immunohistochemistry and FISH analysis.
    Lynnhtun K; Renthawa J; Varikatt W
    Pathology; 2014 Apr; 46(3):211-5. PubMed ID: 24614699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycolytic inhibitor 2-deoxy-d-glucose suppresses cell proliferation and enhances methylprednisolone sensitivity in non-Hodgkin lymphoma cells through down-regulation of HIF-1α and c-MYC.
    Pang YY; Wang T; Chen FY; Wu YL; Shao X; Xiao F; Huang HH; Zhong H; Zhong JH
    Leuk Lymphoma; 2015 Jun; 56(6):1821-30. PubMed ID: 25219592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emetine induces chemosensitivity and reduces clonogenicity of acute myeloid leukemia cells.
    Cornet-Masana JM; Moreno-Martínez D; Lara-Castillo MC; Nomdedeu M; Etxabe A; Tesi N; Pratcorona M; Esteve J; Risueño RM
    Oncotarget; 2016 Apr; 7(17):23239-50. PubMed ID: 26992240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycolytic inhibitor 2-deoxyglucose simultaneously targets cancer and endothelial cells to suppress neuroblastoma growth in mice.
    Huang CC; Wang SY; Lin LL; Wang PW; Chen TY; Hsu WM; Lin TK; Liou CW; Chuang JH
    Dis Model Mech; 2015 Oct; 8(10):1247-54. PubMed ID: 26398947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome.
    Tibiletti MG; Martin V; Bernasconi B; Del Curto B; Pecciarini L; Uccella S; Pruneri G; Ponzoni M; Mazzucchelli L; Martinelli G; Ferreri AJ; Pinotti G; Assanelli A; Scandurra M; Doglioni C; Zucca E; Capella C; Bertoni F
    Hum Pathol; 2009 May; 40(5):645-52. PubMed ID: 19144384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycolytic enzyme hexokinase II is a putative therapeutic target in B-cell malignant lymphoma.
    Nakajima K; Kawashima I; Koshiisi M; Kumagai T; Suzuki M; Suzuki J; Mitsumori T; Kirito K
    Exp Hematol; 2019 Oct; 78():46-55.e3. PubMed ID: 31560931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myc promotes glutaminolysis in human neuroblastoma through direct activation of glutaminase 2.
    Xiao D; Ren P; Su H; Yue M; Xiu R; Hu Y; Liu H; Qing G
    Oncotarget; 2015 Dec; 6(38):40655-66. PubMed ID: 26528759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.